Midtvedt T, Lingaas E, Carlstedt-Duke B, Höverstad T, Midtvedt A C, Saxerholt H, Steinbakk M, Norin K E
Department of Medical Microbial Ecology, Karolinska Institute, Stockholm, Sweden.
APMIS. 1990 Sep;98(9):839-44. doi: 10.1111/j.1699-0463.1990.tb05004.x.
The intestinal microbial conversion of cholesterol to coprostanol has been measured in groups of healthy subjects before, during and after they received the antibiotics ampicillin, bacitracin, clindamycin, co-trimoxazole, doxycycline, erythromycin, metronidazole, nalidixic acid, ofloxacin or vancomycin orally for 6 days. Before they received antibiotics, the subjects demonstrated two distinct patterns of cholesterol conversion. One pattern was characterised by extensive conversion of cholesterol, the other by little or no conversion. Intake of bacitracin, clindamycin, erythromycin, metronidazole and vancomycin significantly reduced the conversion to coprostanol. In the groups receiving ampicillin or doxycycline, marked reductions were found in most of the subjects. No alterations were found in the groups receiving co-trimoxazole, nalidixic acid or ofloxacin. In 6 subjects no conversion of cholesterol to coprostanol was found up to 5 weeks after the end of the antibiotic intake. We conclude that orally given antibiotics may cause alterations in the intestinal conversion of cholesterol, reflecting changes in the anaerobic, Gram-positive component of the gut flora.
在健康受试者口服氨苄西林、杆菌肽、克林霉素、复方新诺明、强力霉素、红霉素、甲硝唑、萘啶酸、氧氟沙星或万古霉素6天之前、期间和之后,对他们肠道微生物将胆固醇转化为粪甾烷醇的情况进行了测定。在接受抗生素治疗之前,受试者表现出两种不同的胆固醇转化模式。一种模式的特征是胆固醇大量转化,另一种模式则是很少或没有转化。摄入杆菌肽、克林霉素、红霉素、甲硝唑和万古霉素会显著降低向粪甾烷醇的转化。在接受氨苄西林或强力霉素的组中,大多数受试者的转化明显减少。在接受复方新诺明、萘啶酸或氧氟沙星的组中未发现变化。在6名受试者中,直到抗生素摄入结束后5周都未发现胆固醇向粪甾烷醇的转化。我们得出结论,口服抗生素可能会导致肠道胆固醇转化发生改变,这反映了肠道菌群中厌氧革兰氏阳性成分的变化。